Veru Inc. (NASDAQ:VERU) Short Interest Update

Veru Inc. (NASDAQ:VERU) was the recipient of a large decrease in short interest in the month of June. As of June 15th, there was short interest totalling 10,450,400 shares, a decrease of 13.0% from the May 31st total of 12,010,000 shares. Based on an average trading volume of 2,642,200 shares, the days-to-cover ratio is currently 4.0 days.

Insiders Place Their Bets

In other news, CEO Mitchell Shuster Steiner sold 28,066 shares of the company’s stock in a transaction that occurred on Friday, May 17th. The stock was sold at an average price of $1.32, for a total value of $37,047.12. Following the transaction, the chief executive officer now owns 7,012,892 shares of the company’s stock, valued at $9,257,017.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 181,970 shares of company stock worth $250,075 over the last three months. Insiders own 14.20% of the company’s stock.

Institutional Investors Weigh In On Veru

A number of hedge funds have recently made changes to their positions in VERU. Cetera Advisors LLC acquired a new stake in Veru in the first quarter valued at $33,000. Ikarian Capital LLC bought a new stake in Veru during the first quarter valued at $663,000. Alpine Global Management LLC grew its holdings in Veru by 21.0% during the 1st quarter. Alpine Global Management LLC now owns 710,000 shares of the company’s stock worth $497,000 after acquiring an additional 122,999 shares during the period. Choreo LLC bought a new position in shares of Veru in the 1st quarter worth about $64,000. Finally, Rosalind Advisors Inc. lifted its stake in shares of Veru by 12.5% in the 1st quarter. Rosalind Advisors Inc. now owns 4,500,000 shares of the company’s stock valued at $3,150,000 after purchasing an additional 500,000 shares during the period. 47.16% of the stock is currently owned by institutional investors and hedge funds.

Veru Price Performance

Shares of VERU opened at $0.88 on Tuesday. The firm has a 50 day simple moving average of $1.14 and a two-hundred day simple moving average of $0.83. The company has a market cap of $128.62 million, a P/E ratio of -2.58 and a beta of -0.43. Veru has a one year low of $0.36 and a one year high of $1.92.

Veru (NASDAQ:VERU) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). The business had revenue of $4.14 million for the quarter, compared to analyst estimates of $3.00 million. Veru had a negative return on equity of 130.13% and a negative net margin of 265.27%. On average, analysts expect that Veru will post -0.27 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on VERU shares. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price target on shares of Veru in a research report on Monday, May 13th. B. Riley initiated coverage on Veru in a research note on Tuesday, May 14th. They issued a “buy” rating and a $5.00 price target for the company. Raymond James assumed coverage on Veru in a research note on Thursday, March 28th. They set an “outperform” rating and a $3.00 price objective on the stock. Finally, Oppenheimer reiterated an “outperform” rating and set a $5.00 target price (down from $7.00) on shares of Veru in a research report on Monday, April 15th.

Veru Company Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.